Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.
Labcorp's CBF 2026 poster summary describes a unified serum free-IgE assay supporting comparison of two IgE-targeting drug candidates, including a marketed comparator. The team evaluated assay conditions that can disturb drug–IgE equilibrium and reports establishing a fit-for-purpose method. The public summary does not identify the therapies or provide numerical validation metrics; it is a conference report.
Based on the article abstract, a review of 20 approved small-molecule medicines for selected chronic inflammatory diseases found more than 25% higher exposure in patients for five medicines, using reported population pharmacokinetic analyses. The authors highlight CYP3A4 and CYP2C19 metabolism. This cross-drug review supports risk assessment, not automatic dose changes for individual patients.
This commentary proposes a lifecycle approach to model-informed decision-making, from discovery and dose selection to regulatory evaluation and reimbursement. It discusses quantitative methods, patient-relevant outcomes, and real-world data, alongside challenges in integration, transparency, and stakeholder acceptance. It is a conceptual roadmap, not a prospective validation of one modeling strategy.
Certara launched Bio Venture Catalyst, bringing together scientific development, regulatory, commercial, and investor-oriented strategy. The announcement includes model-informed development support and asset prioritization. The offering is a consulting service; its stated aims do not demonstrate improved clinical outcomes or guarantee financing.
This perspective examines digital-twin claims against established pharmacometric practice. It argues that individual simulation, sequential updating, and decision-focused uncertainty analysis have longstanding roots in PK/PD modeling. The author emphasizes that fundamental limits, including identifiability, remain relevant despite new terminology.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
